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Temperature-Sensitive Phenotypes of Peroxisome-
Assembly Processes Represent the Milder Forms
of Human Peroxisome-Biogenesis Disorders
To the Editor:
Peroxisome-biogenesis disorders (PBDs) are lethal he-
reditary diseases caused by abnormalities in the assembly
processes of peroxisomes (Moser et al. 1995). The per-
oxisome is a ubiquitous organelle involved in vital met-
abolic functions, such as oxidative processes involving
H2O2, b-oxidation of fatty acids, and biosynthesis of
plasmalogens (Van den Bosch et al. 1992 ). PBDs are
characterized by multiple defects in these functions, as
well as by the lack of morphologically normal peroxi-
somes. They are genetically classified into complemen-
tation groups (CGs), the number of which is x11 (Shi-
mozawa et al. 1993; Moser et al. 1995; Poulos et al.
1995). Each CG contains significantly different clinical
phenotypes—for example, Zellweger syndrome (ZS), ne-
onatal adrenoleukodystrophy (NALD), and infantile
Refsum disease (IRD). ZS patients have severe neuro-
logical abnormalities, dysmorphic features, hepatome-
galy, and multiple renal cysts, and most die at age !6
mo. NALD patients have similar symptoms, but they
survive considerably longer, dying during early child-
hood. In contrast, IRD patients do not exhibit significant
abnormalities in the CNS, and they have the longest
average life span among patients with PBDs (Lazarow
and Moser 1995; Moser et al. 1995). Although the
causal genes (PEXs) for several CGs have been cloned
and the mutations have been identified at the molecular
level (Shimozawa et al. 1992 ; Dodt et al. 1995; Wiemer
et al. 1995; Fukuda et al. 1996; Yahraus et al. 1996;
Chang et al. 1997; Okumoto and Fujiki 1997; Port-
steffen et al. 1997; Reuber et al. 1997), it is unknown
why such diverse clinical phenotypes occur in the same
CGs although, in all CGs, the phenotypes are very sim-
ilar. We report that milder forms of PBDs are charac-
terized by temperature-sensitive (TS) phenotypes of per-
oxisome-assembly processes in the fibroblasts of
patients.
In spite of the variations in the clinical features, the
fibroblasts from patients of all three PBD phenotypes
generally lack peroxisomes. Although the occurrence of
a reduced number of peroxisomes occasionally has been
noted in several PBD cell lines (Arias et al. 1985;Wiemer
et al. 1991; Slawecki et al. 1995), no correlation with
clinical features has been apparent. We assumed that
limited types of leaky mutations in the PEX genes could
be the causes of the milder forms of PBDs. As a possible
parameter representing such leakiness, we examined
temperature sensitivity. Fibroblasts from PBD patients
with different CGs were incubated at 30C and at 37C
and were subjected to immunofluorescence stainingwith
anti-catalase antibody. After 72 h incubation at 30C,
punctate staining of catalase typical of peroxisomes was
detected in the fibroblasts of all six patients with IRD
and in three of five of those with NALD, belonging to
four different CGs (fig. 1b and table 1), whereas no
peroxisomes appeared in the same cells after incubation
at 37C (fig. 1a). Catalase and the 70-kD peroxisomal
membrane protein (PMP70) were colocalized in these
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Figure 1 Immunofluorescence staining of peroxisomes in pa-
tients’ fibroblasts and in Z65 mutant Chinese-hamster-ovary cells.
Cells were cultured for 72 h at either 37C (a, c, and e) or 30C (b,
d, and f) and were stained with either anti–human catalase antibody
(a–d) or anti–rat catalase rabbit antibody (e and f). a and b, Fibroblasts
of an IRD patient (F-05). c and d, Fibroblasts of a ZS patient (F-01).
e and f, Z65 transformant with Pex2E55K. (Scale bar  50 mm)
Table 1
Temperature Sensitivity of Peroxisome Biogenesis in Fibroblasts of
PBD Patients
CG AND
PATIENTa PHENOTYPE
PEROXISOME-
POSITIVE CELLS
INCUBATED ATb
(%)
AGE AT DEATH
OR LAST
FOLLOW-UPc37C 30C
A (8):
A-06 ZS 0 10 4 mo
A-05 NALD 0 90
A-08 NALD 0 80 3 years 1 mo
A-04d IRD 0 60
C (4):
C-03e ZS 0 0 8 mo
C-08 ZS 0 0 4 mo
E (1):
E-14 ZS 0 0 4 mo
E-01f NALD 5 5 2 years 9 mo
E-13 NALD 1 1 1 year 8 mo
E-05d IRD 0 90
E-24 IRD 0 60 1 year 7 mog
E-25 IRD 0 60 10 years 7 mog
E-26 IRD 0 50 6 years 1 mog
F (10):
F-01h ZS 0 0 8 mo
F-04i ZS 0 0 3 mo
F-05 IRD 0 70
)j (6):
6-01 NALD 5 80 4 years 6 mo
a The letter designation is that provided by Gifu University (Japan),
and the number designation (in parentheses) is that provided by the
Kennedy Krieger Institute.
b Data are averages of several view fields, at #200.
c Data are for traceable cases only.
d Purchased from Coriell Cell Repositories (Camden, NJ); the cell
line designations are GM08771 (A-04) and GM08770 (E-05).
e Source: Fukuda et al. (1996).
f Source: Maeda et al. (1990).
g Parents were alive after the age at the last follow-up (i.e., age
shown).
h Source: Shimozawa et al. (1992).
i Source: Shimozawa et al. (1998).
j No designation of CG was available from Gifu University.
cells after incubation for 72 h at 30C (data not shown),
thereby confirming the identity of these catalase-positive
granules as peroxisomes. In the fibroblasts of ZS patients
with any CGs tested, no peroxisomes were found at
either 30C or 37C incubation (fig. 1c and d and table
1). Fibroblasts of normal controls had punctate patterns
of catalase at both 30C and 37C incubation (data not
shown).
We confirmed the formation of functional peroxi-
somes in the TS cells at 30C, on the basis of three
biochemical criteria: the peroxisomal b-oxidation activ-
ity of very-long-chain fatty acids (Suzuki et al. 1991),
the activity of peroxisomal dihydroxyacetonephosphate
acyltransferase (Shimozawa et al. 1988) involved in the
plasmalogen biosynthesis, and the proteolytic processing
of peroxisomal acyl-CoA oxidase (Tsukamoto et al.
1995), which occurs within the peroxisomes. These ac-
tivities were deficient in the ZS cells (F-01), at both 30C
and 37C incubation, whereas in the TS cells (F-05),
these functions were markedly improved by incubation
at 30C but not by incubation at 37C (data not shown).
To identify the mutation responsible for the TS phe-
notype, the PEX2 gene (GenBank), the causal gene for
CG-F (Shimozawa et al. 1992), was amplified by PCR
from the genomic DNA of TS cells F-05. PCR reaction
was performed by use of PEX2 gene–specific antisense
(complementary to the PEX2 cDNA sequence of posi-
tions 967–991, 5′-ATA CTT AGG ATG ACT AAT ATT
AAG-3′) and sense (an intron sequence of the PEX2
gene, starting 48 bp upstream of the 5′ end of the coding
exon, 5′-CAA GAT TGC AAC TCT TTG CTA ATG-3′)
oligonucleotides. PCR conditions were as follows: initial
heating for 1 min at 94C, followed by 40 cycles of
denaturation for 1 min at 94C, annealing for 2 min at
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55C, and extension for 3 min at 72C. Nucleotide-se-
quence comparison with the normal PEX2 gene revealed
that this patient was heterozygous for two point mu-
tations. One was a GrA substitution at nucleotide po-
sition 163,, relative to the A residue of the initiation
codon, causing an amino acid alteration (E55K). The
other was a CrT substitution at nucleotide position 355,
resulting in the change of the codon 119 to a stop codon,
TGA (R119 Stop). These two mutations were also found
in the PEX2 cDNA obtained by reverse transcrip-
tase–PCR of the mRNA from F-05. The latter nonsense
mutation is identical to that reported by Shimozawa et
al. in both ZS patient F-01 (Shimozawa et al. 1992) and
another CG-F patient (Shimozawa et al. 1993) (both
cases were homozygous for the mutation), and it pre-
viously had been established that this mutation is non-
functional. Accordingly, we investigated the relationship
between the E55K mutation and the TS phenotype, by
gene transfection. The PEX2E55K gene sequence sub-
cloned in the expression vector pUcD2SRaMCS (Tsu-
kamoto et al. 1995 ) was transfected to a PEX2-deficient
Chinese-hamster-ovary cell mutant (Z65) (Tsukamoto et
al. 1991, 1994), and stable transformants were pro-
duced. The transformants revealed a punctate distribu-
tion of catalase after 72 h incubation at 30C, whereas
no catalase-positive granules were observed for incu-
bation at 37C (fig. 1e and f); Z65 transfected with wild-
type PEX2 had catalase-positive granules at both 30C
and 37C; and the cells transfected with the empty vector
exhibited no peroxisomal staining at either 30Cor 37C
(data not shown). Thus, the TS phenotype of peroxisome
biogenesis of the IRD fibroblasts (F-05) is caused by the
E55K mutation of the PEX2 gene.
The present results indicate that the peroxisome-as-
sembly process is TS in the fibroblasts of patients with
the mildest form of PBD (i.e., IRD), irrespective of CGs,
and that this phenotype is directly linked to the specific
genotype of the responsible PEX gene, at least in F-05.
Such a TS phenotype was not observed for the most
severe form of PBD (i.e., ZS), whereas only a subset of
the cell lines were TS for NALD, the intermediate form
of PBD. In this regard, it is interesting to note that the
NALD patients with the TS phenotype (patients A-08
and 6-01) had longer life spans than did those with the
non-TS phenotype (patients E-01 and E-13), even
though the latter two patients exhibited slight leakiness
at both temperatures. Thus, the TS phenotypes of per-
oxisome assembly in the cultured fibroblasts represent
the mildness of the clinical symptoms of PBD. Patients
with the TS phenotypes may be mosaic for peroxisome
occurrence from cell to cell in the body at normal body
temperatures. A mosaicism of peroxisomes was indeed
reported in the liver of a PBD patient who had a rela-
tively long life span (Giros et al. 1996). It is also possible
that TS patients have partially functional peroxisomes.
In any case, the TS patients probably have higher gross
peroxisomal activities than do the patients with non-TS
leaky phenotypes (patients E-01 and E-13).
Temperature- or cold-sensitive phenotypes have been
noted in a few genetic diseases. In epidermolysis bullosa
simplex, the disturbance of the skin becomes worse at
higher temperatures, whereas, in paramyotonia congen-
ita, exposure to lower temperatures causes myotonia. In
these instances, the symptoms are understood to be di-
rect effects of the temperature- and cold-sensitive phe-
notypes of the corresponding gene products, keratin
(Morley et al. 1995) and Na-channel protein (Mc-
Clatchey et al. 1992), respectively. In maple syrup–urine
disease, symptoms sometimes worsenwhen there is a
high fever (Chuang and Shih 1995); however, the re-
sponsible mutation has not been identified. Thus, TS
phenotypes directly linked to specific genotypes possibly
occur in various genetic diseases. Among these, PBD
cases are unique in that a complex cellular process, per-
oxisome assembly, becomes TS because of a single gene
mutation, causing distinct clinical features.
Our present results would raise several clinical impli-
cations. First, the severity of prognosis could be diag-
nosed, by examination of the temperature sensitivity of
peroxisome assembly in the fibroblasts of newborn PBD
patients. Second, precaution against fever may be nec-
essary in the treatment TS PBD patients. Third, hypo-
thermal therapy might be applicable to TS PBD patients.
Such therapy might increase the frequency of cells having
functional peroxisomes, thereby improving clinical
symptoms.
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Figure 1 Pedigree of family 232. Blackened circles indicate affected women; blackened squares indicate affected men; and a diagonal
slash indicates that the patient is deceased. Individual identification numbers appear directly below the symbols. Breast cancer is indicated with
age at diagnosis (“dx”); bilateral breast cancer is indicated (“bil”) with ages at diagnoses; “PSU” indicates primary site not known; and “TAH-
BSO” indicates a complete abdominal hysterectomy, including bilateral oophorectomy. The plus sign () indicates the presence of the BRCA1
G2508T mutation and the BRCA2 3295insA mutation, in the proband tested. The minus sign () indicates the absence of these two mutations
in BRCA1 and BRCA2.
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A Breast Cancer Patient of Scottish Descent with
Germ-Line Mutations in BRCA1 and BRCA2
To the Editor:
Ramus et al. (1997) previously described an Ashkenazi
Jewish patient found to have germ-linemutations in both
breast and ovarian cancer–susceptibility genes, BRCA1
and BRCA2. We report the first such example for the
non-Jewish Caucasian population. The patient, who is
indicated by an arrow in pedigree 232 (fig. 1), was of
Scottish origin. She was diagnosed with breast cancer
(grade 2 adenocarcinoma) at age 35 years. Simultaneous
screening by protein truncation test of both BRCA1
(exon 11) and BRCA2 (exon 11) detected truncating
